1. Craig, J. R., Peters, R. L., Edmondson, H. A. & Omata, M. Fibrolamellar Carcinoma of the Liver: A Tumor of Adolescents and Young Adults with Distinctive Clin ico-pa tho logic Fea tu res. doi:10.1002/1097-0142.
2. O’Neill, A. F. et al. Fibrolamellar carcinoma: An entity all its own. Curr. Probl. Cancer 45, 100770 (2021).
3. Honeyman, J. N. et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 343, 1010–1014 (2014).
4. Ramai, D., Ofosu, A., Lai, J. K., Gao, Z. H. & Adler, D. G. Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study. Dig. Dis. Sci. 66, 308–314 (2021).
5. Lalazar, G. et al. Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening. Cancer Discov. 11, 2544–2563 (2021).
6. El-Serag, H. B. & Davila, J. A. Is Fibrolamellar Carcinoma Different from Hepatocellular Carcinoma? A US Population-Based Study. Hepatology 39, 798–803 (2004).
7. Pawlik, T. & Lafaro, K. Fibrolamellar hepatocellular carcinoma: current clinical perspectives. J. Hepatocell. carcinoma 2, 151 (2015).
8. Lemekhova, A. et al. Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience. World J. Surg. Oncol. 18, (2020).
9. Mayo, S. C. et al. Treatment and Prognosis of Patients with Fibrolamellar Hepatocellular Carcinoma: A National Perspective. J. Am. Coll. Surg. 218, 196 (2014).
10. Graham, R. P. et al. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. Mod. Pathol. 31, 141–149 (2018).
11. Sempokuya, T. et al. Survival characteristics of fibrolamellar hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results database study. World J. Clin. Oncol. 13, 352–365 (2022).
12. Hirsch, T. Z. et al. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. J. Hepatol. 72, 924–936 (2020).
13. Surjan, R. C., dos Santos, E. S., Basseres, T., Makdissi, F. F. & Machado, M. A. A proposed physiopathological pathway to hyperammonemic encephalopathy in a non-cirrhotic patient with fibrolamellar hepatocellular carcinoma without ornithine transcarbamylase (OTC) mutation. Am. J. Case Rep. 18, 234–241 (2017).
14. Khanani, A. M. et al. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map. JAMA Ophthalmol. 140, 20–28 (2022).
15. Hastings, W. K. Monte carlo sampling methods using Markov chains and their applications. Biometrika 57, 97–109 (1970).
16. Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected communities. Sci. Reports 2019 91 9, 1–12 (2019).
17. El Dika, I. et al. A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma. Oncologist 25, 925-e1603 (2020).
18. Abou-Alfa, G. K. et al. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. Oncologist 25, e1837–e1845 (2020).
19. Solipuram, V. et al. Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma. Hepatology 74, 2899–2901 (2021).
20. Chapuy, C. I., Sahai, I., Sharma, R., Zhu, A. X. & Kozyreva, O. N. Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm. Oncologist 21, 514–520 (2016).